Go to the Globe and Mail homepage

Jump to main navigationJump to main content


Globe Investor

Inside the Market

Up-to-the-minute insights
on developing market news

Entry archive:

Is Valeant’s valuation less than the sum of its parts? Add to ...

Subscribers Only

The plan for Valeant Pharmaceuticals International Inc. is to press on, restoring its reputation under new management and reviving its collection of businesses without doing the deal making that boosted revenue and profit for so long. All the while, of course, negotiating the minefield of headline risk from further potential problems and reassuring lenders that it can pay down its massive debt load.

Report Typo/Error

Follow us on Twitter: @GlobeInvestor

Also on The Globe and Mail

Valeant shakeup: Ackman in, Pearson out (BNN Video)

Next story